The editor's roundtable: pathophysiology and management of hyponatremia and the role of vasopressin antagonists.
نویسندگان
چکیده
Dr. Friedewald is a consultant for AstraZeneca, Wilmington, Delaware. Dr. Emmett has no relevant financial relationships to disclose. Dr. Gheorghiade has received compensation for speaking, advising, consulting, and providing educational programs from Abbott Laboratories, Abbott Park, Illinois; Astellas Pharma US, Inc., Deerfield, Illinois; AstraZeneca; Bayer Schering Pharma, Pittsburgh, Pennsylvania; Corthera, San Carlos, California; DebioPharm, Lausanne, Switzerland; Errekappa, Milan, Italy; Glaxo SmithKline, Research Triangle Park, North Carolina; Johnson & Johnson, New Brunswick, New Jersey; Medtronic, Inc., Minneapolis, Minnesota; Merck & Company, Whitehouse Station, New Jersey; Novartis Pharma, East Hanover, New Jersey; Otsuka America Pharmaceutical, Inc.; PeriCor Therapeutics, New York, New York; Protein Design Laboratories, Incline Village, Nevada; Sanofi-Aventis, Bridgewater, New Jersey; Sigma Tau, Indianapolis, Indiana; and Solvay Pharmaceuticals, Marietta, Georgia. Dr. Roberts has received compensation for speaking from Merck & Company and AstraZeneca.
منابع مشابه
Vasopressin antagonists: role in the management of hyponatremia.
Hyponatremia is a common electrolyte disorder associated with potentially serious or life-threatening consequences. Serum osmolality and sodium concentration [Na+] are regulated by thirst, the hormone arginine vasopressin (AVP), and renal water and sodium handling. Hyponatremia is frequently caused by dysregulation of AVP, which accompanies disorders of water retention, such as congestive heart...
متن کاملHyponatremia revisited: translating physiology to practice.
The complexity of hyponatremia as a clinical problem is likely caused by the opposite scenarios that accompany this electrolyte disorder regarding pathophysiology (depletional versus dilutional hyponatremia, high versus low vasopressin levels) and therapy (rapid correction to treat cerebral edema versus slow correction to prevent osmotic demyelination, fluid restriction versus fluid resuscitati...
متن کاملEcstasy (MDMA) and its effects on kidneys and their treatment: a review
Ecstasy (MDMA; 3,4-methylenedioxymethylamphetamine) is an illicit drug that has been increasingly abused by young people. Its effects include euphoria, enhanced sociability and heightened mental awareness. These come about via the increase of serotonin in both the central nervous system and the sympathetic nervous system. Despite the drug’s prevalent abuse, serious or adverse effects are rare. ...
متن کاملVasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?
In the congestive heart failure (CHF) setting, chronic hyponatremia is very common. The present review aims at addressing topics relevant to the pathophysiology of hyponatremia in the course of CHF as well as its optimal treatment, including the main advantages and the limitations resulting from the use of the available dietary and pharmacological measures approved for the treatment of this ele...
متن کاملVasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses
Decreases in the concentration of sodium in plasma constitute hyponatremia, the commonest electrolyte disorder in clinical medicine. It is now well established that its presence conveys an increased mortality risk even when the decrement is mild. In addition, recent evidence suggests that chronic and apparently asymptomatic hyponatremia is associated with increased morbidity including neurocogn...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The American journal of cardiology
دوره 107 9 شماره
صفحات -
تاریخ انتشار 2011